Ignite Creation Date:
2024-05-06 @ 4:52 PM
Last Modification Date:
2024-10-26 @ 2:17 PM
Study NCT ID:
NCT05112731
Status:
TERMINATED
Last Update Posted:
2024-02-16
First Post:
2021-10-20
Brief Title:
Role of Glycation and Inflammation in Acute Ischemic Heart Disease
Sponsor:
GEK Srl
Organization:
GEK Srl
Study Overview
Official Title:
Action of Glycation and Inflammation in Operative Ischemic Heart Disease
Status:
TERMINATED
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Missing enrollment at study centre
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AGLIANICO
Brief Summary:
This study requires the consecutive enrollment of 60 patients following the first event of acute myocardial infarction evaluating B-Cell Activating Factor BAFF and methylglyoxal MGO levels in the acute setting pre-reperfusion and 3 months after reperfusion
Detailed Description:
This study requires the consecutive enrollment of 60 patients at admission for first acute myocardial infarction At enrollment before reperfusion a blood sample is obtained to measure B-Cell Activating Factor BAFF and methylglyoxal MGO levels in the acute setting This measure is then repeated at follow-up visit 3 months after reperfusion The aim of the study is to identify specific subsets of patients and evaluate biomarkers variations
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None